The profit of the Italian pharmaceutical company Recordati rose 6.5% in 2025 to 443.6 million euros, due to a higher operating result and the reduction in financial costs, the company said in a statement this Friday.
According to the same note, “consolidated net revenue for the full year 2025 was R$2,618 million, an increase of 11.8% compared to 2024”.
EBITDA (profit before taxes, interest, depreciation and amortization) was 991.1 million euros in 2025, an increase of 14.5% compared to the previous year and financial charges were 89.5 million euros, a reduction of 2.1 million euros compared to 2024.
Net debt on December 31, 2025 was 2,037.3 million euros, corresponding to a leverage ratio slightly lower than 2.1 times EBITDA, compared to a net debt of 2,154.3 million euros on December 31, 2024.
The Italian company also has financial targets for the 2026 fiscal year of net revenue between 2,730 and 2,800 million euros, as well as an EBITDA of between 995 and 1,030 million euros.
Leave a Reply